HDHendrika M. Duivenvoorden

Hendrika M. Duivenvoorden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hendrika M. Duivenvoorden has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    “Don’t Pretend We Don’t Exist” - Experiences of Sex and Gender Inclusivity in Science Classrooms

    by Evangelia Kakavas, Jessica K. Abbonizio, Connor J. Bayly-Jones, Michelle D. Lazarus, Hendrika M. Duivenvoorden

    As visibility and self-identification among LGBTQIA+ individuals continue to rise in many countries, so does the societal need to consider this community in traditionally heteronormative spaces. Higher education science classrooms are often enforcing rigid binaries and featuring language that marginalizes transgender and gender non-conforming (TGNC) individuals. This can result in TGNC individuals lacking a connection to their science identity, and ultimately leaving science altogether. Despite this, research delving into the experiences and comfort levels of science students and educators especially regarding inclusive language and practices in classrooms is limited. This case study assessed the comfort levels of different sexual orientation and gender identity groups in the classroom, and identified inclusive and exclusionary practices, such as the use of pronouns, that could influence an individual’s science identity. Employing a mixed-methods design, we surveyed students and staff in science at an Australian University. Reflexive thematic analysis of open responses ( n = 108) alongside statistical analysis of quantitative responses ( n = 109), revealed TGNC individuals (28% of student respondents) reported more frequently feeling unsafe or excluded by their peers and teaching staff in class, compared to gender-conforming individuals. Predominant qualitative themes and narratives included the persistence of cis-normativity (the societal assumption that everyone identifies with the sex they were assigned at birth, and this is the norm), the harm of cis-normative language and practices, and the fostering of safety through inclusive language and practices in science classes. We discuss recommendations for inclusive pedagogical practices, which have broad applicability to foster students’ feelings of inclusion in any classroom.

  • Open Access

    Investigating the Role of Heparanase in Breast Cancer Development Utilising the MMTV-PyMT Murine Model of Mammary Carcinoma

    by Krishnath M. Jayatilleke, Hendrika M. Duivenvoorden, Gemma F. Ryan, Belinda S. Parker, Mark D. Hulett

    Breast cancer is the second most common human malignancy and is a major global health burden. Heparanase (HPSE) has been widely implicated in enhancing the development and progression of solid tumours, including breast cancer. In this study, the well-established spontaneous mammary tumour-developing MMTV-PyMT murine model was utilised to examine the role of HPSE in breast cancer establishment, progression, and metastasis. The use of HPSE-deficient MMTV-PyMT (MMTV-PyMTxHPSE−/−) mice addressed the lack of genetic ablation models to investigate the role of HPSE in mammary tumours. It was demonstrated that even though HPSE regulated mammary tumour angiogenesis, mammary tumour progression and metastasis were HPSE-independent. Furthermore, there was no evidence of compensatory action by matrix metalloproteinases (MMPs) in response to the lack of HPSE expression in the mammary tumours. These findings suggest that HPSE may not play a significant role in the mammary tumour development of MMTV-PyMT animals. Collectively, these observations may have implications in the clinical setting of breast cancer and therapy using HPSE inhibitors.


  • Open Access

    Figure S2 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

    by Natasha K. Brockwell, Katie L. Owen, Damien Zanker, Alex Spurling, Jai Rautela, Hendrika M. Duivenvoorden, Nikola Baschuk, Franco Caramia, Sherene Loi, Phillip K. Darcy, et al.

  • Open Access

    Figure S3 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

    by Natasha K. Brockwell, Katie L. Owen, Damien Zanker, Alex Spurling, Jai Rautela, Hendrika M. Duivenvoorden, Nikola Baschuk, Franco Caramia, Sherene Loi, Phillip K. Darcy, et al.

  • Open Access

    Supplementary figure legends from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

    by Natasha K. Brockwell, Katie L. Owen, Damien Zanker, Alex Spurling, Jai Rautela, Hendrika M. Duivenvoorden, Nikola Baschuk, Franco Caramia, Sherene Loi, Phillip K. Darcy, et al.

  • Open Access

    Figure S1 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

    by Natasha K. Brockwell, Katie L. Owen, Damien Zanker, Alex Spurling, Jai Rautela, Hendrika M. Duivenvoorden, Nikola Baschuk, Franco Caramia, Sherene Loi, Phillip K. Darcy, et al.

  • Open Access

    High-content siRNA 3D co-cultures to identify myoepithelial cell-derived breast cancer suppressor proteins

    by Hendrika M. Duivenvoorden, Natasha K. Brockwell, Cameron J. Nowell, Kaylene J. Simpson, Belinda S. Parker

    Understanding how cancer cells interact with the surrounding microenvironment early in breast cancer development can provide insight into the initiation and progression of invasive breast cancers. The myoepithelial cell layer surrounding breast ducts acts as a physical barrier in early breast cancer, preventing cancer cells from invading the surrounding stroma. Changes to the expression profile and properties of myoepithelial cells have been implicated in progression to invasive carcinoma. Identifying the molecular drivers of myoepithelial cell-mediated tumour suppression may offer new approaches to predict and block the earliest stages of cancer invasion. We employed a high-content approach to knock down 87 different genes using siRNA in an immortalised myoepithelial cell line, prior to co-culture with invasive breast cancer cells in 3D. Combined with high-content imaging and a customised analysis pipeline, this system was used to identify myoepithelial proteins that are necessary to control cancer cell invasion. This dataset has identified prospective myoepithelial suppressors of early breast cancer invasion which may be used by researchers to investigate their clinical validity and utility.


  • Open Access

    Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC

    by Natasha K. Brockwell, Jai Rautela, Katie L. Owen, Linden J. Gearing, Siddhartha Deb, Kate Harvey, Alex Spurling, Damien Zanker, Chia-Ling Chan, Helen E. Cumming, et al.

    Patients diagnosed with triple negative breast cancer (TNBC) have an increased risk of rapid metastasis compared to other subtypes. Predicting long-term survival post-chemotherapy in patients with TNBC is difficult, yet enhanced infiltration of tumor infiltrating lymphocytes (TILs) has been associated with therapeutic response and reduced risk of metastatic relapse. Immune biomarkers that predict the immune state of a tumor and risk of metastatic relapse pre- or mid-neoadjuvant chemotherapy are urgently needed to allow earlier implementation of alternate therapies that may reduce TNBC patient mortality. Utilizing a neoadjuvant chemotherapy trial where TNBC patients had sequential biopsies taken, we demonstrate that measurement of T-cell subsets and effector function, specifically CD45RO expression, throughout chemotherapy predicts risk of metastatic relapse. Furthermore, we identified the tumor inherent interferon regulatory factor IRF9 as a marker of active intratumoral type I and II interferon (IFN) signaling and reduced risk of distant relapse. Functional implications of tumor intrinsic IFN signaling were demonstrated using an immunocompetent mouse model of TNBC, where enhanced type I IFN signaling increased anti-tumor immunity and metastasis-free survival post-chemotherapy. Using two independent adjuvant cohorts we were able to validate loss of IRF9 as a poor prognostic biomarker pre-chemotherapy. Thus, IRF9 expression may offer early insight into TNBC patient prognosis and tumor heat, allowing for identification of patients that are unlikely to respond to chemotherapy alone and could benefit from further immune-based therapeutic intervention.


  • Open Access

    Sustainable Syntheses of (−)-Jerantinines A & E and Structural Characterisation of the Jerantinine-Tubulin Complex at the Colchicine Binding Site

    by Christopher J. Smedley, Paul A. Stanley, Mohannad E. Qazzaz, Andrea E. Prota, Natacha Olieric, Hilary Collins, Harry Eastman, Andrew S. Barrow, Kuan-Hon Lim, Toh-Seok Kam, et al.

    The jerantinine family of Aspidosperma indole alkaloids from Tabernaemontana corymbosa are potent microtubule-targeting agents with broad spectrum anticancer activity. The natural supply of these precious metabolites has been significantly disrupted due to the inclusion of T. corymbosa on the endangered list of threatened species by the International Union for Conservation of Nature. This report describes the asymmetric syntheses of (−)-jerantinines A and E from sustainably sourced (−)-tabersonine, using a straight-forward and robust biomimetic approach. Biological investigations of synthetic (−)-jerantinine A, along with molecular modelling and X-ray crystallography studies of the tubulin—(−)-jerantinine B acetate complex, advocate an anticancer mode of action of the jerantinines operating via microtubule disruption resulting from binding at the colchicine site. This work lays the foundation for accessing useful quantities of enantiomerically pure jerantinine alkaloids for future development.